Meda AB
Sunday 12 June 2016, 10:30 – 12:00
Strauss 1+2

Chair:   Herbert Riechelmann, Austria

Herbert Riechelmann, Austria

Uncontrolled allergy – from atopic dermatitis to allergic rhinitis to anaphylaxis
Nikos Papadopoulos, Greece

Control gaps – time for an update?
Jean Bousquet, France

Taking control of allergy – armoury to better symptom relief
Dermot Ryan, United Kingdom

Herbert Riechelmann, Austria

Novartis Pharma AG
Sunday 12 June 2016, 13:30 – 15:00
Strauss 3

50 years of IgE: What we’ve learnt and envisioning the future

Chair: William Busse, United States

Welcome and introduction
Chair: William Busse, United States

Dendritic cells: New findings about their role in allergic inflammation
Oscar Palomares, Spain

Prevention of exacerbation: Restoring the imbalance between allergic inflammation and anti-viral defence
William Busse, United States

Defining allergic asthma: Can we do better?
Adnan Custovic, United Kingdom


50 years of IgE: Envisioning the future
William Busse, United States

Sunday 12 June, 2016, 15:30 – 17:00
Hall A2

HDM respiratory allergy: A global solution to a worldwide challenge

J Christian Virchow, Germany
Victòria Cardona, Spain

Why is the worldwide challenge of HDM respiratory allergy so comprehensive?
Glenis Scadding, United Kingdom

SQ HDM SLIT-tablet, a global solution

  • Evidence from North America
    Hendrik Nolte, United States
  • Evidence from Japan
    Kimihiro Okubo, Japan
  • Evidence from Europe
    Victòria Cardona, Spain

Conclusions and new outlook
J Christian Virchow, Germany

Questions & Answers

Thermo Fisher Scientific
Monday 13 June 2016, 10:45 – 12:15
Hall A3

Allergen Components in Precision Medicine
Chair: Rudolf Valenta, Austria

From allergen extracts to molecular allergology – Towards prediction of allergy
Rudolf Valenta, Austria

Cracking the secrets of nut allergies by component resolved diagnostics?
Barbara Ballmer-Weber, Switzerland

IgE to Fel d 4 – An emerging predictor of asthma morbidity
Elizabeth Matsui, United States

A molecular approach in diagnosis of mite allergy and asthma
Paolo Matricardi, Germany

Allergopharma GmbH & Co. KG
Monday, 13 June 2016, 13.45 – 15.15

Hall B1

AIT 3.0 – The next step
Chair:   Petra Zieglmayer, Austria

Innovative clinical endpoints in AIT studies
Roy Gerth van Wijk, The Netherlands

Accelerated, flexible, modern – new evidence for pollen allergoids
Adam Chaker, Germany

Optimizing the dose in mite AIT
Marek Jutel, Poland


Stallergenes Greer
Monday 13 June 2016, 15:45 – 17:15
Hall A2

Introducing a patient centric approach to AIT: The three pillars of patient centricity in allergy immunotherapy

Ulrich Wahn, Germany
Zsolt Szepfalusi, Austria

First pillar: Understanding our patients’ needs
Nerin Bahceciler,Turkey

Second pillar: Putting patients at the centre of quality,optimal treatment and adherence to allergy immunotherapy
Carmen Vidal, Spain

Third pillar: Bridging the gap from patients’ needs to physicians’ practice
Pascal Demoly, France

Tuesday June 14, 2016, 10:30 – 12:00
Strauss 3

Marcus Maurer, German
G. Walter Canonica, Italy

Chairs’ welcome and introduction
Marcus Maurer, Germany and G. Walter Canonica, Italy

Rupatadine anti-PAF effect as an added value in the treatment of allergic disorders.
Rosa Muñoz-Cano, Spain

Offering clinical safety and improving Quality of Life to meet patient’s needs.
Claus Bachert, Belgium

A safe ally in the allergic patient’s everyday life.
Marek Kowalski, Poland

Discussion and concluding remarks moderated by
Marcus Maurer, Germany and G. Walter Canonica, Italy

HAL Allergy
Tuesday 14 June, 2016, 13:30 – 15:00
Hall B1

Nikos Papadopoulos, UK/Greece
Ludger Klimek, Germany

Efficacy and safety results from a European Phase III trial with a sublingual birch allergen extract
Oliver Pfaar, Germany

Subcutaneous allergoid immunotherapy for the treatment of house dust mite allergy
Herbert Riechelmann, Austria

A novel SCIT product for peanut allergy from bench to clinic
Carsten Bindslev-Jensen, Denmark